Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
Costello RT, Zerazhi H, Charbonnier A, de Colella JM, Alzieu C, Poizot-Martin I, Cohen R, Bardou VJ, Xerri L, Olive D, Nezri M, Lepeu G, Gastaut JA. Costello RT, et al. Among authors: charbonnier a. Cancer. 2004 Feb 15;100(4):667-76. doi: 10.1002/cncr.20019. Cancer. 2004. PMID: 14770420 Free article. Clinical Trial.
Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
Popovici C, Charbonnier A, Gisserot O, Aguilon P, Rémy V, Olschwang S, Mozziconacci MJ. Popovici C, et al. Among authors: charbonnier a. Leuk Res. 2008 Feb;32(2):361-2. doi: 10.1016/j.leukres.2007.03.001. Epub 2007 Apr 6. Leuk Res. 2008. PMID: 17412419 No abstract available.
Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product.
Calmels B, Lemarié C, Esterni B, Malugani C, Charbonnier A, Coso D, de Colella JM, Deconinck E, Caillot D, Viret F, Ladaique P, Lapierre V, Chabannon C. Calmels B, et al. Among authors: charbonnier a. Transfusion. 2007 Jul;47(7):1268-75. doi: 10.1111/j.1537-2995.2007.01267.x. Transfusion. 2007. PMID: 17581163
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Nicolini FE, Hayette S, Legros L, Rousselot P, Maloisel F, Tulliez M, Guerci A, Charbonnier A, Prébet T, Rigal-Huguet F, Chabane K, Magaud JP, Paillet C, Pivot C, Michallet M. Nicolini FE, et al. Among authors: charbonnier a. Leuk Res. 2011 Jan;35(1):80-6. doi: 10.1016/j.leukres.2010.04.010. Epub 2010 Jun 3. Leuk Res. 2011. PMID: 20605207 Clinical Trial.
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.
Prebet T, Etienne A, Devillier R, Romeo E, Charbonnier A, D'incan E, Esterni B, Arnoulet C, Blaise D, Vey N. Prebet T, et al. Among authors: charbonnier a. Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18. Cancer. 2011. PMID: 20957721 Free article.
278 results